The purpose of this study is to explore the factors that can affect the development ofsevere cases in hospitalized patients with COVID-19, including basic diseases, laboratoryparameters, and clinical manifestations; In addition,to explore whether Azvudine canreduce the mortality of hospitalized patients with COVID-19.
4201 COVID-19 patients discharged from our hospital were enrolled. Binary logistic
regression analysis and ROC curve were used to investigate the role of comorbidities,
laboratory parameters and clinical manifestation on progression of COVID-19 patients. We
used propensity-score models conditional on baseline characteristics and Univariate Cox
regression model to examine whether Azvudine can reduce the mortality of COVID-19
patients.
Drug: Azvudine
Received antiviral treatment with azvudine
Inclusion Criteria:
The COVID-19 positive patients
Exclusion Criteria:
1. patients treated with both azvudine and monotamivir;
2. patients receiving other antiviral drugs such as nematavir/ritonavir;
3. age < 18 years old
The Fifth Affiliated Hospital of Sun Yat-sen University
Zhuhai, Guangdong, China
Not Provided